Revue francophone des laboratoires : RFL最新文献

{"title":"Difficultés inédites des cliniques et hôpitaux privés : une pétition nationale","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00295-8","DOIUrl":"10.1016/S1773-035X(24)00295-8","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 20"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraités expatriés, quand on doit prouver qu'on est toujours en vie !","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00298-3","DOIUrl":"10.1016/S1773-035X(24)00298-3","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 22"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maladie de l'homme de pierre : une molécule sur la voie de garage ?","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00282-X","DOIUrl":"10.1016/S1773-035X(24)00282-X","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 11"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chikungunya : I'EMA recommande Ixchiq pour l'immunisation des adultes","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00284-3","DOIUrl":"10.1016/S1773-035X(24)00284-3","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Pages 12-13"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Les cancers thyroïdiens : diagnostic et suivi","authors":"Jean Guibourdenche , Antonin Ginguay , Marie-Clémence Leguy , Fidéline Bonnet-Serrano","doi":"10.1016/S1773-035X(24)00307-1","DOIUrl":"10.1016/S1773-035X(24)00307-1","url":null,"abstract":"<div><h3>Résumé</h3><div>>Les cancers thyroïdiens sont souvent diagnostiqués lors de l’exploration d’un nodule thyroïdien. Ils se développent aux dépens des cellules folliculaires et sont majoritairement différenciés (papillaire ou vésiculaire) et de bon pronostic, plus rarement peu différenciés et exceptionnellement anaplasiques de pronostic sombre. Les carcinomes médullaires se développent aux dépens des cellules C et s’intègrent dans 25 % des cas à une NEM2 associée à une mutation du proto-oncogène RET. Le bilan thyroïdien est souvent normal. Le diagnostic repose sur l’échographie, qui caractérisera le ou les nodules thyroïdiens à ponctionner ainsi que les adénopathies cervicales. L’examen cyto-histologique établit le diagnostic et la classification de la tumeur déterminant traitement et suivi. On réalisera une thyroïdectomie totale ou partielle, associée ou non à un curage ganglionnaire. L’hypothyroïdie est quasi constante en post-opératoire et justifie une supplémentation à vie par L-thyroxine. Pour les cancers différenciés, une posologie freinatrice associée à un traitement adjuvant par irathérapie (<sup>131I</sup>) est indiquée dans les formes à haut risque de récidive. La surveillance biologique repose sur la thyroglobuline sérique, indétectable en l’absence de récidive. Pour les carcinomes médullaires, le suivi biologique repose sur la calcitonine, indétectable en l’absence de persistance ou de récidive, et sur l’antigène carcino-embryonaire (ACE) sériques. La recherche d’une mutation du gène RET doit être systématique.</div></div><div><h3>Abstract</h3><div>Thyroid cancers are often diagnosed during the exploration of a thyroid nodule. They are developed at the expense of follicular cells mainly differentiated of papillary or vesicular types and associated with a good prognosis, more rarely of oncocytic type and exceptionally of anaplastic type, associated with a poor prognosis. Medullary thyroid carcinomas are developed at the expense of C cells and are part of a MEN 2, associated with a proto-oncogene RET mutation in 25% of cases. Thyroid function is generally conserved. Diagnosis is based on ultrasound, which will characterize the thyroid nodule(s) and the cervical adenopathies to be punctured. The cyto-histological examination establishes the definitive diagnosis and the classification of the tumor determining the management and follow-up. A total or partial thyroidectomy is performed, possibly associated with lymph node removal. Hypothyroidism is quasi-systematic after surgery requiring a supplementation by L-thyroxine. In thyroid differentiated carcinomas, a high L-thyroxine dosage to suppress TSH and an adjuvant iratherapy (1131) are recommended in the forms with high risk of recurrence. Biological follow-up relies on serum thyroglobulin, indetectable in the absence of relapse. In the case of medullary carcinoma, biological follow-up relies on serum calcitonin, indetectable in the absence of persistence or recurrence and carcin","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Pages 62-68"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"« La Clinique, La Clinique, La Clinique est dans la place…. »","authors":"Thierry Jo Molina (Anatomie et cytologie pathologiques Hôpitaux universitaires Robert-Debré et Necker-Enfants malades)","doi":"10.1016/S1773-035X(24)00270-3","DOIUrl":"10.1016/S1773-035X(24)00270-3","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 1"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142432997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le Rwanda, un modèle de maîtrise du HIV","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00279-X","DOIUrl":"10.1016/S1773-035X(24)00279-X","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 9"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynécologie médicale : une spécialité en détresse","authors":"Jean-Marie Manus","doi":"10.1016/S1773-035X(24)00280-6","DOIUrl":"10.1016/S1773-035X(24)00280-6","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 565","pages":"Page 10"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Des vaccins contre la dengue imparfaits mais indispensables","authors":"Pr Jean-Daniel Lelièvre MD/PhD","doi":"10.1016/S1773-035X(24)00259-4","DOIUrl":"10.1016/S1773-035X(24)00259-4","url":null,"abstract":"","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 564","pages":"Pages 24-29"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quel avenir pour la transfusion ?","authors":"Olivier Garraud (professeur émérite d’immunologie)","doi":"10.1016/S1773-035X(24)00261-2","DOIUrl":"10.1016/S1773-035X(24)00261-2","url":null,"abstract":"<div><h3>Résumé</h3><p>La transfusion sanguine est toujours un support dans les situations d’urgence hémorragique traumatique comme elle l’est depuis plus d’un siècle, et elle l’est devenue dans certaines situations d’urgence médicale. Le profil des donneurs de sang s'est modifié au cours du xx^e siècle et c’est très notable depuis les années 1950. Cependant, le profil des receveurs a également considérablement changé et <strong>évolue</strong> constamment, en particulier dans les situations où la transfusion représente une hémothérapie. En appui de cela, les produits sanguins bénéficient des progrès de la technique tant pour leur production que pour la prévention des effets indésirables qu’ils peuvent entraîner. La qualité et la surveillance des produits sanguins et de leur application a aussi conduit à de nouvelles disciplines, comme l’hémovigilance et de nouveaux protocoles comme la mise en œuvre de la gestion optimisée du sang et de sa gestion personnalisée. Deux sujets restent en suspens cependant, la promotion d’études cliniques mieux standardisées et ainsi plus informatives d’une part, et l’expansion de technologies innovatrices et de rupture pouvant un jour se substituer à la transfusion d'autre part. Dans ces circonstances, la transfusion sanguine est irremplaçable et le restera probablement pendant plusieurs décennies encore.</p></div><div><h3>Abstract</h3><p>Blood transfusion is still a support in traumatic hemorrhagic emergencies, as it has been for over a century, and has become so in certain medical emergencies. The profile of blood donors has evolved over the course of this century, most notably since the second half of the 20th century. However, the profile of recipients has also changed considerably and is constantly evolving, particularly in situations where transfusion is allocated through hemotherapy. In support of this, blood products benefit from technical advances both in their production and in the prevention of the undesirable effects they can cause. The quality and monitoring of blood products and their application has also led to new disciplines, such as hemovigilance, and new protocols, such as the implementation of optimized blood management and personalized blood management. Two issues remain unresolved, however: on the one hand, the promotion of more standardized and therefore more informative clinical studies, and on the other, the expansion of innovative, disruptive technologies that could one day replace transfusion. In these circumstances, blood transfusion is irreplaceable and will probably remain so for many decades to come.</p></div>","PeriodicalId":74728,"journal":{"name":"Revue francophone des laboratoires : RFL","volume":"2024 564","pages":"Pages 32-37"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}